The Chris Sandburg Insider Financial piece pushes the idea that the LH market should be more lucrative and accessible than the HIV market. He suggests that we stop butting our heads up against the HIV wall (Gilead dominates that market, and they would no doubt try to use their influence to protect their stake -- maybe they already have) and focus on LH, where there are no known competitors yet, and 1 in 10 people Covid sufferers worldwide need help. Makes sense to me.

Sandburg doesn't mention it, I think, but if LH patients may need 8 doses instead of 2-4, then that translates into a lot more revenue per patient.

Not to mention, of course, helping a ton of people who really need help. Add interior exclamation point.